Stryker Cyberattack ‘Meaningfully’ Impacted Q1
Stryker reported first‑quarter sales of $6 billion, a 2.6% year‑over‑year increase that fell short of its typical 10‑12% growth pace. The slowdown stems from a March 11 cyberattack that shut down ordering, shipping and manufacturing for several weeks, wiping 40,000 laptops and disrupting revenue capture. CEO Kevin Lobo said the incident "meaningfully" impacted results, but the company kept its full‑year guidance of 8‑9.5% organic sales growth and $14.90‑$15.10 adjusted EPS. Analysts expect a rebound in Q2 and view the long‑term outlook as still strong.
Redo TAVR: Supra-Annular, Intra-Annular Valves Linked to Comparable Outcomes
A study of 172 redo transcatheter aortic valve replacement (TAVR‑in‑TAVR) procedures from the international PANDORA registry shows comparable one‑year outcomes regardless of whether the initial and second valves are supra‑annular or intra‑annular. The median interval between the index and redo...
Cost Management, Outpatient Unit Helped Tenet Weather Volume Headwinds in Q1
Tenet Healthcare posted $702 million profit on $5.4 billion revenue in Q1, beating Wall Street forecasts despite a 90‑basis‑point drop in acute‑care volumes and a 0.3% dip in outpatient admissions. The operator’s cost‑management program and a strong performance from its ambulatory surgical...
AHA Federal Funding Requests Include Workforce Development for Rural Communities
The American Hospital Association (AHA) has asked Congress to allocate federal funds for 2027 healthcare workforce programs, targeting the chronic staffing gaps in rural America. In letters to House and Senate leaders, the AHA, representing roughly 5,000 hospitals and clinicians,...
Patients Facing Barriers to Care Most Likely to Be No-Shows
A scoping review of 22 U.S. dermatology studies identified young age, minority race/ethnicity, lack of insurance and limited English proficiency as the strongest predictors of patient no‑shows. Adults 19‑25 were 2.3 times more likely to miss appointments, while Black and Hispanic...
Acelyrin Founder Shao-Lee Lin Emerges at Cue, as It Becomes Latest to License From China
Cue Biopharma announced a strategic reboot, appointing Acelyrin founder Shao‑Lee Lin to its executive team and unveiling a new allergy drug candidate sourced from research labs in Taiwan and mainland China. The Boston‑based company, previously focused on T‑cell immunotherapies, will...
Aster DM Targets 15,000 Beds by FY30 Post Merger with Quality Care
Aster DM Healthcare is finalizing its merger with Blackstone‑backed Quality Care by the end of June 2026. The combined company plans to boost its operating margin from the current 21% to roughly 23‑24% within three years. Management projects adding over...
Save the Date: Premium Subscriber-Exclusive Post-Hoc Live
Endpoints News announced a premium‑only Post‑Hoc Live event that will break down Q1 earnings after a deal‑heavy first quarter. The live session promises real‑time analysis, interactive Q&A with analysts, and deeper insight into the companies that drove the quarter’s performance....
How BJC HealthCare Got Better at Advanced Care Planning Discussions
BJC HealthCare, a 14‑hospital system, built a machine‑learning algorithm to flag patients at high risk of dying within 30 days and trigger opt‑out advanced care planning (ACP) conversations. By standardizing provider training and embedding the workflow across inpatient, ICU, primary‑care...
Q&A: AI Platform Targets Clinical Chart Insights Beyond LLM Limits
Dyania Health’s Synapsis AI platform tackles clinical chart review by answering precise, context‑driven questions rather than producing generic summaries. The system was built on roughly 25,000 physician‑annotated hours and is designed to surface nuanced signals for care decisions, trial eligibility, and...
China Never Actually Removed Homosexuality From Its Official List of Mental Disorders
The article debunks the long‑held belief that China removed homosexuality from its official mental‑disorder list in 2001. In fact, the Chinese Classification of Mental Disorders‑3 (CCMD‑3) retained "homosexuality" as a diagnosis, labeling it "not necessarily abnormal" while still allowing conversion‑therapy...
The 'Broken Handoff' Leaving Retirees Lost on Medicare Choices
Retirees exiting employer‑sponsored health plans often receive only a COBRA notice, leaving a "broken handoff" to Medicare advisers. Without coordinated guidance, many miss the initial enrollment window, incurring lifelong premium penalties and suboptimal plan choices. The issue affects roughly 10,000...
Microbiome-Based Therapy Gains FDA Fast Track in Ulcerative Colitis
Belgium‑based MRM Health announced that its investigational microbiome‑based therapy MH002 has been granted FDA fast track designation for mild‑to‑moderate ulcerative colitis. MH002 is a live biotherapeutic composed of six defined commensal bacterial strains designed to restore gut microbial balance and...
CAQH Index Finds $20 Billion in Cost Savings Opportunities
The 2025 CAQH Index, which surveys 600 provider organizations covering 63% of insured lives, estimates over $20 billion in cost‑saving opportunities if automation of medical and dental workflows is expanded. Electronic prior‑authorization adoption rose to 40%, while other electronic processes remained...
FDP, Palantir and Global Counsel: Under Mandelson's Long Shadow
The NHS’s Federated Data Platform (FDP) was awarded to US data‑analytics firm Palantir in 2023. A letter highlights that Palantir hired Global Counsel, a lobbying firm co‑founded by former Labour minister Peter Mandelson, who was recently dismissed as the UK’s ambassador...
Non-Tobacco Nicotine Products Tied to Pregnancy, Labor Complications
A multi‑institutional study of 77,549 pregnant patients presented at the ACOG meeting found that non‑tobacco nicotine use—primarily vaping and nicotine pouches—significantly raises the risk of adverse pregnancy outcomes, including preterm labor, cesarean delivery, and maternal death. Relative risks ranged from...
GLP-1 Pills Are Here: Can Employers Afford to Cover Weight-Loss Drugs?
Oral GLP‑1 weight‑loss pills are entering the market as employers grapple with whether to add them to health benefits. A 2025 KFF survey shows only 19% of firms with 200+ workers covered GLP‑1s, but coverage jumps to 43% among companies...
How Expert Radiology Scaled a National Teleradiology Practice
Expert Radiology Management Services, founded in 2020, has built a national subspecialty teleradiology network that now spans all 50 states, 350+ imaging facilities, and a 26‑physician team. By adopting RamSoft’s PowerServer with PowerReader, the practice achieved sub‑6‑second study loading and...
Syngene Sees Pipeline Traction, Bets on Biologics for Growth Beyond FY27
Syngene International posted a modest 2% revenue rise to ₹1,037 crore (~$125 m) in Q4 FY26, while profit after tax fell 16% to ₹153 crore (~$18 m) due to exceptional costs and a key biologics client’s destocking. Margins compressed, with EBITDA margin dropping to...
Moderna Beats Revenue Expectations with $389M, but Litigation Dogs Earnings
Moderna reported first‑quarter revenue of $389 million, roughly 50% above analysts’ expectations, while vaccine sales reached $352 million, beating consensus. A $950 million upfront settlement with Arbutus over lipid‑nanoparticle patents pushed the net loss to $1.3 billion, though it was still better than the...
Cycling for Weight Loss: GLP-1s
GLP‑1 medications like Wegovy and Ozempic are increasingly used for weight loss, but they can blunt hunger and thirst signals, making proper fueling critical for cyclists. Bicycling’s guide, hosted by Ryan Grewell and nutritionist Namrita Brooke, outlines how to combine...
‘A Powerful Tool for Respect’: Birth Plans Improve Maternal, Neonatal Outcomes
A systematic review and meta‑analysis presented at the ACOG annual meeting found that birth plans significantly improve maternal and neonatal outcomes. Women with a birth plan were over three times more likely to have a spontaneous vaginal delivery and to...
Why Clinical Digital Out-of-Home Displays Are Healthcare’s Most Untapped Advertising Opportunity
Clinical digital out‑of‑home (DOOH) screens sit in waiting rooms where patients are fully attentive to a health concern, yet they are priced at the same CPM as mass‑media channels that cannot guarantee an audience. Studies show point‑of‑care ads generate 84%...
Proactive Planning Can Mitigate Quantum Migration Failures
Healthcare IT leaders face an imminent shift to quantum computing that could overwhelm existing infrastructure and compromise patient data security. Mike Nelson, field CTO of digital trust at DigiCert, urges a coordinated migration timeline to avoid care disruptions as organizations...
How Healthcare Can Prepare for Quantum Computing
Health systems are being urged to modernize legacy IT and develop migration roadmaps after NIST officially approved a suite of post‑quantum cryptographic algorithms. Mike Nelson, DigiCert’s field CTO, warns that existing encryption in electronic medical records and patient portals is...
Policy Watch: FDA Looks to Expand Real-Time Drug Clinical Trials
The FDA has launched an AI‑driven pilot that streams clinical‑trial data in real time for AstraZeneca and Amgen’s lymphoma and lung‑cancer studies, and is now seeking public input to broaden the approach. The Ninth Circuit Court declined to compel the...
Gut Microbe’s Sulfated Bile Acid Eases Pediatric Sepsis
Researchers identified deoxycholic acid 3‑sulfate (DCA‑3S) as a gut‑derived metabolite that mitigates pediatric sepsis. Metabolomic and metagenomic analyses revealed Enterococcus raffinosus as the primary producer, accounting for over 80 % of DCA‑3S synthesis. In mouse models, DCA‑3S restored intestinal barrier integrity and dampened...
STAT+: Axsome Wins FDA Nod for Alzheimer’s Agitation
Axsome Therapeutics announced that the U.S. Food and Drug Administration has granted a regulatory nod for its investigational therapy aimed at treating agitation in Alzheimer’s disease. The agency’s decision clears the path for accelerated clinical development, potentially moving the drug...
How Medicare Blocks Access to Lifesaving Treatments
Medicare’s Coverage with Evidence Development (CED) policy has limited access to transcatheter aortic valve replacement (TAVR), a minimally invasive heart‑valve procedure, for millions of seniors with severe aortic stenosis. Although TAVR became the clinical standard of care by 2017, Medicare...
Novel Pulsed Field Ablation Technology ‘Works’
A first‑in‑human trial of Pulse Biosciences' nanosecond pulsed‑field ablation (CellFX nsPFA 360) treated 177 patients with paroxysmal atrial fibrillation. The catheter delivered >10,000 V nanosecond pulses, achieving 100% acute lesion success and 91% durability at 2‑3 months. At one year, 89.7% of patients remained free...
Re: GMC: Doctors to Get New Rules on Their Personal Beliefs and Work
The General Medical Council (GMC) is set to introduce new rules governing how doctors may invoke personal beliefs in clinical practice. The proposal clarifies that conscientious objection is permissible only when it does not lead to discrimination or denial of...
The Multimodal Explosion: Why 2026 Breaks the AI Paradigm
In 2026 AI transitions from isolated tools to multimodal platforms that fuse transcripts, labs, notes, and device data, closing the "Synthesis Gap" in clinical workflows. This integration enables "minimal‑click" medicine, surfacing critical information in real time and freeing clinicians to...
AI: Are Psychiatric Times, MJH Life Sciences the Past or Future of Psychiatry?
The article contends that Psychiatric Times, owned by MJH Life Sciences, has contributed little to neuroscience‑driven psychiatry despite four decades of publication, a shortcoming that becomes stark as AI mental‑health therapists gain traction. It argues that meaningful progress requires linking...
Peptides Are Unproven as Health Aids. FDA May Unleash Them Anyway
The FDA is poised to broaden access to injectable peptides by allowing compounding pharmacies to produce them and by considering their inclusion in oral dietary supplements. Health and Human Services Secretary Robert F. Kennedy Jr. has publicly opposed what he...
Drug Trials Snapshot: TRYNGOLZA
TRYNGOLZA (olezarsen), an APOC‑III‑directed antisense oligonucleotide, received FDA approval on December 19, 2024 for adults with familial chylomicronemia syndrome (FCS). In the pivotal Phase 3 trial (NCT04568434), 66 patients from 11 countries received monthly 80 mg injections or placebo for 53 weeks. The drug achieved...
A System Failing by Design: Lessons From Two Decades of Deferred Reform
The 2006 NHS dental contract, built around a unit‑of‑activity model, incentivises high‑volume, low‑prevention care, prompting a wave of conscientious dentists to leave the system. Practices are now returning roughly £900 million in NHS funding because the payment structure is financially unsustainable...
Programmable RNA Targeting via DNA-Guided CRISPR-Cas12a
A team of molecular biologists has reengineered the CRISPR‑Cas12a nuclease to cleave RNA using a DNA guide, creating a programmable RNA‑targeting platform. The DNA‑guided Cas12a system achieved up to 90% knockdown of endogenous transcripts in human cell lines and functioned...
Drug Trials Snapshot: ALYFTREK
Vertex Pharmaceuticals received FDA approval for ALYFTREK, a triple‑combination CFTR modulator, on Dec. 20, 2024. The drug targets cystic fibrosis patients aged six and older with at least one F508del or other responsive mutation. Approval was based on two 52‑week, non‑inferiority trials...
AI Telehealth Startup MEDVi Draws Scrutiny Over Marketing, Compliance
MEDVi, an AI‑powered telehealth startup specializing in weight‑loss drugs, has surged to hundreds of millions in revenue while operating with a minimal staff. On Feb. 20, 2026 the FDA issued a warning letter accusing the company of false and misleading claims about...
Direct-To-Consumer Drug Portals Offer Lower Prices, But Preserve Inequities
President Trump launched TrumpRx, a federal direct‑to‑consumer portal that sells dozens of prescription drugs at cash‑pay discounts. The program relies on confidential three‑year agreements with 17 manufacturers, using most‑favored‑nation pricing tied to nine wealthy nations. While the portal lowers out‑of‑pocket...
Drug Trials Snapshot: ROMVIMZA
Deciphera's ROMVIMZA (vimseltinib) received FDA approval on Feb 17 2025 for adult tenosynovial giant‑cell tumor (TGCT) when surgery is unsuitable. Approval was based on a global phase II trial of 123 patients, showing a 40% overall response rate versus 0% with placebo...
Summit Slips on Ivonescimab's Apparent Interim Miss in Sign of Investor Frustration
Summit Therapeutics’ shares plunged almost 20% after an interim analysis of its Phase 3 trial of ivonescimab showed a statistical shortfall in a key efficacy endpoint. The miss was limited to a subgroup analysis, but investors interpreted it as a signal...
Amgen Files Update to Tavneos Label as FDA Escalates Push to Withdraw
Amgen filed a supplemental application to revise the prescribing information for its rare‑disease drug Tavneos (avacopan) as the FDA intensifies its effort to withdraw the product. The label update seeks to add new safety warnings and monitoring requirements after the...
5 Questions to Consider When Choosing a Birth Control Method
Choosing a birth control method involves weighing hormonal versus non‑hormonal options, each with distinct efficacy rates ranging from 87% to 99% for typical use. The article outlines five key questions—effectiveness, daily management, medical compatibility, future fertility plans, and STI risk—to...
AJMC® in the Press, May 1, 2026
The CDC paused diagnostic testing for mpox and rabies as part of a strategic laboratory downsizing, shifting initial confirmation duties to state and local public‑health labs. This change raises concerns about treatment delays, especially for post‑exposure prophylaxis. The pause was...
GoodRx Partners with Novo Nordisk to Offer Self-Pay Pricing for New Oral Ozempic® Pill
GoodRx has teamed with Novo Nordisk to sell the newly launched oral Ozempic® pill at transparent self‑pay rates, ranging from $149 to $299 per month depending on dosage. The tiered pricing covers the 1.5 mg, 4 mg and 9 mg strengths, letting patients...
If AI Replaces Radiologists, Who Owns The Outcome?
The article argues that AI will not replace radiologists; instead, it reshapes the responsibility chain in imaging care. While AI can accelerate detection and reduce workload, the radiologist’s role in communicating findings and ensuring follow‑up remains essential. The real challenge...
Peer Support and Case Management: Complementary, Not Interchangeable
The article clarifies that case managers and peer support specialists, while both essential in behavioral health, serve distinct functions and should not be used interchangeably. Case managers coordinate services, handle Medicaid, housing, and compliance, whereas peer specialists provide relational, lived‑experience...
Amgen Positions MariTide as Potential ‘Best Monthly’ Obesity Drug
Amgen is positioning its bispecific antibody‑peptide MariTide as the premier monthly or less‑frequent obesity treatment. The company launched a Phase 3 MARITIME‑Switch study to evaluate switching patients from weekly GLP‑1 injections to four‑to‑six monthly doses. Phase 2 data showed up to a...
Top Psychiatrists Call for a Greater Focus on Ceasing Medication
Health Secretary Robert F. Kennedy Jr. is pushing to curb psychiatric drug use, prompting leading psychiatrists to draft deprescribing guidance. The group, convened by the American Society of Clinical Psychopharmacology, released initial recommendations in JAMA Network Open and the British Journal...